Palmitoyl Tetrapeptide-7

The glycine–glutamine–proline–arginine sequence is joined to palmitic acid, intended to assist skin delivery. Its peptide portion comes from an immunoglobulin fragment. Sederma supplies it as Rigin, and it is paired with palmitoyl tripeptide-1 in Matrixyl 3000. It is a cosmetic signal peptide, not a drug or collagen replacement.

Cell experiments and supplier findings report lower interleukin-6 inflammatory signaling. The rationale links persistent low-grade “inflammaging” to enzymes that break down collagen: moderating that signaling might help skin retain a firmer appearance. Laboratory behavior is not proof of a clinical outcome or of treating inflammation with a cosmetic.

There is no FDA drug approval for this cosmetic ingredient. Ordinary cosmetics do not undergo drug-style preapproval; they may describe appearance and feel, whereas claims to treat inflammation or alter body structure can fall under drug regulation.

Soothing and age-appearance creams and serums commonly combine it with palmitoyl tripeptide-1. The intended appearance goals are calmer-looking, less red skin and less visible fine lines; it also appears in formulas marketed for sensitive skin.

A human multi-peptide-serum study included this ingredient, but other actives prevent attributing the result to palmitoyl tetrapeptide-7 alone. Specific benefit claims rely largely on manufacturer in-use panels. An independent review also identifies poor skin penetration as a practical limitation. The available literature contains no independent single-ingredient human efficacy trial.

Topical cosmetic use is generally considered well tolerated with low irritation potential. Individual responses differ, so a sensitive-skin patch test remains reasonable despite the ingredient’s soothing positioning.